Sirnaomics Biopharmaceuticals

Sirnaomics is a clinical-stage biopharmaceutical company specializing in the discovery and development of RNA therapeutics for oncology and fibrotic diseases. Headquartered in the United States with significant operations in China, the company utilizes its proprietary Polypeptide Nanoparticle (PNP) and GalNAc-based GalAhead delivery platforms to overcome the challenges of nucleic acid drug delivery. Their lead candidate, STP705, is a dual-targeting siRNA therapeutic currently in late-stage clinical trials for non-melanoma skin cancer and hypertrophic scarring. Beyond oncology, Sirnaomics is expanding its pipeline into metabolic diseases, anti-viral applications, and liver-targeted therapies. The company is listed on the Hong Kong Stock Exchange and maintains a robust portfolio of intellectual property surrounding its delivery technologies.